High-grade, poorly differentiated breast carcinoma mimicking primary breast lymphoma: a case report of a diagnostic dilemma Authors: Sarada Khadka, Ashish Sapkota, Priyanka Regmi, Rajan Shah, Ishwor Tiwari, Dikshya Thadarai Published: 2026 ABSTRACT Background:High-grade breast carcinomas can occasionally exhibit morphological and immunophenotypic features resembling hematolymphoid neoplasms, leading to diagnostic confusion. Accurate diagnosis is essential to guide appropriate therapy.Case presentation:We report a 35-year-old female presenting with a rapidly enlarging right breast mass. Core biopsy revealed sheets of atypical lymphoid-like cells. Immunohistochemistry (IHC) showed positivity for cytokeratin, progesterone receptor, CD10, CD117, and BCL2, while CD20, CD3, estrogen receptor, and HER2 were negative, with Ki-67 > 95%. Despite initial suspicion of primary breast lymphoma, the overall clinicopathologic correlation favored a diagnosis of high-grade, poorly differentiated invasive breast carcinoma.Discussion:This case highlights a rare diagnostic pitfall where breast carcinoma mimics lymphoma. Careful histopathologic evaluation, comprehensive IHC profiling, and clinicopathologic correlation are crucial to avoid misdiagnosis and ensure timely management.Conclusion:Awareness of such mimicry can prevent unnecessary hematolymphoid-directed therapy. Introduction Breast lymphomas account for less than 0.5% of all malignant breast tumors, with the first report by Bobrotina et al in 1959[1,2]. The breast is an uncommon site of extranodal Hodgkin lymphoma (HL). It usually represents a heterogeneous group of malignancies that originate from the lymphoid system as a painless palpable mass[3]. Because it mimics a benign tumor and bears similarity to breast carcinoma, primary breast non-HL is rarely detected through clinical and radiological screening[4]. Due to non-specific imaging findings, the diagnosis is established by biopsy and immunohistochemistry (IHC), with treatment based on a combination of chemotherapy and radiotherapy[5].HIGHLIGHTSReports a high-grade, poorly differentiated breast carcinoma mimicking primary breast lymphoma, creating a diagnostic dilemma.Shows morphologic overlap and an aberrant immunohistochemistry (IHC) profile (CD10, CD117, BCL2 positive; CD20, CD3 negative), misleading initial diagnosis.Emphasizes the importance of comprehensive IHC panels and clinicopathologic correlation to resolve diagnostic ambiguities.Provides practical guidance to avoid misdiagnosis and inappropriate therapy in aggressive breast tumors with lymphoma-like features. HIGHLIGHTS Reports a high-grade, poorly differentiated breast carcinoma mimicking primary breast lymphoma, creating a diagnostic dilemma. Reports a high-grade, poorly differentiated breast carcinoma mimicking primary breast lymphoma, creating a diagnostic dilemma. Shows morphologic overlap and an aberrant immunohistochemistry (IHC) profile (CD10, CD117, BCL2 positive; CD20, CD3 negative), misleading initial diagnosis. Shows morphologic overlap and an aberrant immunohistochemistry (IHC) profile (CD10, CD117, BCL2 positive; CD20, CD3 negative), misleading initial diagnosis. Emphasizes the importance of comprehensive IHC panels and clinicopathologic correlation to resolve diagnostic ambiguities. Emphasizes the importance of comprehensive IHC panels and clinicopathologic correlation to resolve diagnostic ambiguities. Provides practical guidance to avoid misdiagnosis and inappropriate therapy in aggressive breast tumors with lymphoma-like features. Provides practical guidance to avoid misdiagnosis and inappropriate therapy in aggressive breast tumors with lymphoma-like features. Here, we report a case of high-grade breast carcinoma suspected to be lymphoma, highlighting the diagnostic pitfalls and the importance of accurate clinicopathological and immunohistochemical evaluation. This case report has been prepared in accordance with the SCARE Criteria[6]. Case presentation A 33-year-old woman initially presented with a self-detected progressive lump in her right breast, noted approximately 7–8 months prior to presentation, accompanied by ulceration of the overlying skin for the past 5–6 months. On detailed history-taking, it emerged that she had been diagnosed with invasive ductal carcinoma of the right breast a year earlier, for which she was advised to undergo neoadjuvant chemotherapy consisting of adriamycin and cyclophosphamide (AC) followed by paclitaxel. However, she completed only two cycles of chemotherapy, during which she noted a remarkable improvement, and subsequently discontinued follow-up, remaining lost to the oncology care system for a year – a gap that would later prove crucial in her disease progression. Upon her return to the breast and endocrine surgical outpatient department, she presented with a markedly enlarged and ulcerated mass fixed to the overlying skin and underlying structures, measuring approximately 10 × 10 cm in the outer quadrant of the right breast, as shown in Figures 1 and 2 along with ipsilateral axillary lymphadenopathy. Systemic examination was unremarkable, with no systemic signs of distant metastases. Figure 1.Frontal view of the right breast showing a solitary exophytic ulceroproliferative mass with areas of necrosis arising from the upper outer quadrant of the right breast. Figure 2.Close-up view of the right breast lesion showing irregular ulcerated fungating mass with central necrosis and surrounding skin involvement. Frontal view of the right breast showing a solitary exophytic ulceroproliferative mass with areas of necrosis arising from the upper outer quadrant of the right breast. Close-up view of the right breast lesion showing irregular ulcerated fungating mass with central necrosis and surrounding skin involvement. Magnetic resonance imaging (MRI) of the breast revealed a well-defined, lobulated mass with restricted diffusion located in the outer quadrant of the right breast, infiltrating the breast parenchyma, right pectoralis muscles, and the subcutaneous tissue planes, suggestive of an aggressive malignant lesion. A core needle biopsy under ultrasound guidance was obtained, revealing a tumor that was estrogen receptor (ER) negative and human epidermal growth factor receptor 2 (HER2/neu) negative, but with progesterone receptor (PR) positivity scored 6/8 on immunohistochemistry. Computed tomography (CT) scans of the chest and abdomen showed no evidence of distant metastasis, confirming localized advanced disease. Clinical staging was established as T4b N3a M0. Given this staging, the multidisciplinary team planned to resume neoadjuvant chemotherapy to downstage the tumor before surgical intervention. The patient underwent four additional cycles of AC, followed by paclitaxel chemotherapy, demonstrating a partial response, following which she underwent a right modified radical mastectomy (MRM) with an extensive axillary lymph node dissection, including level III nodes. Intraoperatively, a 7 × 6 cm ulcerative lesion was noted in the upper outer quadrant of the right breast, with extensive involvement of the overlying skin and underlying pectoralis major muscle. Level III lymph nodes were enlarged and suspicious for metastatic involvement. Histopathological examination of the mastectomy specimen revealed a high-grade carcinoma composed of pleomorphic epithelial cells arranged in sheets and nests, showing prominent nucleoli, coarse chromatin, frequent atypical mitoses, and extensive geographic necrosis – a morphology raising initial suspicion for high-grade lymphoma, likely Burkitt’s lymphoma. All surgical resection margins were free of tumor infiltration. The histological features are shown in Figures 3 and 4. The surprise came with immunohistochemistry: the tumor showed positivity only for CD10, CD117, CK, and BCL2, while markers such as CD20, CD3, MPO, CD30, CD1A, CD138, CD4, CD2, CD34, ALK, and TdT were negative. Among these, some markers are regarded as consistent with lymphoma of B-cell or T-cell origin, causing a diagnostic enigma. However, the tumor was PR-positive (6/8), ER- and HER2-negative, with a Ki-67 index exceeding 80%, pointing toward an extremely aggressive, hormone receptor-poor breast carcinoma. Ki-67 and CK status of the tumor is shown in Figures 5 and 6. With the inconclusive IHC profile, the clinico-pathologic correlation confirmed the diagnosis of a high-grade, poorly differentiated invasive carcinoma of the breast. The impression: an elusive and aggressive tumor masquerading as lymphoma. Figure 3.Section examination (4×) revealing proliferation of tumor cell 2–3 times larger than mature lymphocytes, displaying a cord-like architecture at periphery along with large area of necrosis. Figure 4.Monotonous cells (40×) with vesicular chromatin, inconspicuous to visible nucleoli, and scanty cytoplasm along with atypical mitotic figures infiltrating the adjacent fatty tissues. Figure 5.Tumor cell with high Ki-67 (> 80%). Figure 6.Tumor cells positive for CK (AE1/AE3). Section examination (4×) revealing proliferation of tumor cell 2–3 times larger than mature lymphocytes, displaying a cord-like architecture at periphery along with large area of necrosis. Monotonous cells (40×) with vesicular chromatin, inconspicuous to visible nucleoli, and scanty cytoplasm along with atypical mitotic figures infiltrating the adjacent fatty tissues. Tumor cell with high Ki-67 (> 80%). Tumor cells positive for CK (AE1/AE3). Postoperatively, the patient received adjuvant radiotherapy to the chest wall and regional lymphatics, delivering a total dose of 40 Gy in 16 daily fractions over 3 weeks, with each fraction administered at 2.5 Gy/day. The patient was closely followed, during which initial follow-up was uneventful. However, 7 months after surgery, the patient presented again with a new palpable lump in the right axilla, which, on biopsy, revealed metastatic recurrence. The mass was excised surgically, but unfortunately, the disease progression was relentless. Four months later, she developed neurological symptoms, including right arm weakness, accompanied by dyspnea, cough, and abdominal pain. Repeat contrast enhanced computed topography of the chest and abdomen showed multiple aggressive lesions consistent with recurrence and metastasis. A large right anterior chest wall mass invaded the 3rd–5th costochondral junctions with mediastinal extension. Additional deposits were seen in the right pleura and right upper lung, with minimal pleural effusion and a small hypodense lesion involving the right diaphragmatic pleura extending to the liver capsule. PET-CT revealed fluorodeoxyglucose-avid lesions in the left breast and axillary nodes, suggesting either synchronous primary or metastasis. Despite such multimodality aggressive treatment consisting of radiotherapy, chemotherapy, and surgery, along with close surveillance, the patient’s clinical condition deteriorated, and she succumbed during ongoing therapy, underscoring the aggressive nature and poor prognosis of advanced breast carcinoma with disrupted treatment and unusual tumor biology. Discussion This case presents a formidable diagnostic challenge: a high-grade, poorly differentiated breast carcinoma that, on routine histomorphology, convincingly mimicked a malignant lymphoma, specifically raising suspicion for Burkitt’s lymphoma. The primary cause of diagnostic confusion was the striking morphological overlap. The tumor exhibited a “small blue round cell” appearance with sheets of discohesive, monotonous cells exhibiting high nuclear-to-cytoplasmic ratios, vesicular chromatin, and frequent mitoses, alongside extensive geographic necrosis – a classic picture of a high-grade hematolymphoid malignancy like Burkitt or diffuse large B-cell lymphoma (DLBCL)[7]. The cord-like architecture at the periphery further compounded this impression. In such scenarios, the pathologist’s initial differential is rightly skewed toward lymphoid and other small round cell tumors, especially when the clinical history of a rapidly growing, ulcerative mass is non-specific. This morphological mimicry triggered a lymphoma-centric IHC workup, which paradoxically deepened the enigma. The tumor’s negativity for standard lymphoid markers (CD20, CD3, CD30, TdT) effectively ruled out most common B-cell, T-cell, and precursor lymphomas. However, the positivity for CD10 and BCL2, markers frequently associated with germinal center B-cell lymphomas, provided a false trail[8]. CD10, in particular, is a well-known marker in Burkitt lymphoma and a subset of DLBCL[9]. It was this aberrant co-expression of CD10 and BCL2 in an otherwise lineage-negative, high-grade tumor that cemented the initial suspicion of an unusual lymphoma, leading to the expansion of the IHC panel to include rarer markers. The diagnostic resolution came from a return to first principles and clinico-pathologic correlation. First, the persistent focal positivity for PR (6/8) and cytokeratin (CK), albeit focal, provided the crucial anchor. While breast carcinomas are typically negative for CD10, its expression, though rare (reported in < 5% of cases), is documented in high-grade, metaplastic, and basal-like subtypes and is taken as a worse prognosis factor[10]. CD117 (c-KIT) positivity, while often associated with gastrointestinal stromal tumors, is also variably reported in aggressive breast carcinomas[11]. The final, definitive evidence was the correlation with the patient’s established clinical history of a previously diagnosed invasive ductal carcinoma. When faced with a diagnostically ambiguous high-grade tumor in the breast of a young woman, the pre-test probability of a bizarre, de-differentiated carcinoma recurrence vastly exceeds that of an exceedingly rare primary breast lymphoma with an aberrant immunophenotype. The updated WHO Classification of Tumors of the Breast acknowledges that poorly differentiated carcinomas can pose significant diagnostic difficulty and require extensive IHC for lineage confirmation[12]. Our case amplifies this warning. The critical learning point is the necessity of a parallel, rather than sequential, diagnostic approach. When morphology suggests a small round cell tumor, the initial IHC panel must simultaneously include both epithelial (e.g., CKpan and EMA) and lymphoid (e.g., CD45, CD20, and CD3) markers, along with site-specific markers (e.g., ER, PR, GATA3 for breast), even if the morphology seems “classic” for one lineage. Reliance on a stepwise, morphology-driven algorithm can lead to confirmatory bias and delay the correct diagnosis. Furthermore, the extremely high Ki-67 proliferation index (>80%), while consistent with high-grade lymphomas, is also a hallmark of very aggressive carcinomas and should not be used in isolation to assign lineage[13]. The clinical trajectory of rapid local progression and metastatic spread, despite multimodality therapy, is tragically more characteristic of a highly aggressive, hormone receptor-negative breast carcinoma than of a primary breast lymphoma, which often shows a favorable prognosis[14,15]. This aggressive course may be attributed to delayed definitive diagnosis, incomplete initial therapy, or intrinsically high-risk tumor biology. Conclusion This case provides a critical learning point for clinicians and pathologists: to avert diagnostic confusion when morphology suggests lymphoma, a structured, parallel immunohistochemical approach must be employed from the outset, simultaneously testing for epithelial, lymphoid, and site-specific markers to avoid confirmatory bias from aberrant antigens like CD10. Ultimately, the definitive safeguard is proactive multidisciplinary correlation; the accurate diagnosis was achieved not by a single test but by actively integrating the patient’s clinical history of prior breast carcinoma with the full pathological profile, underscoring that such integration in a tumor board setting is essential for correctly classifying deceptive high-grade malignancies and guiding appropriate therapy.